BG104092A - Сd154 блокадна терапия за лечение на белтък инхибиторен синдром - Google Patents

Сd154 блокадна терапия за лечение на белтък инхибиторен синдром

Info

Publication number
BG104092A
BG104092A BG104092A BG10409200A BG104092A BG 104092 A BG104092 A BG 104092A BG 104092 A BG104092 A BG 104092A BG 10409200 A BG10409200 A BG 10409200A BG 104092 A BG104092 A BG 104092A
Authority
BG
Bulgaria
Prior art keywords
treatment
blockade therapy
protein inhibition
inhibition syndrome
syndrome
Prior art date
Application number
BG104092A
Other languages
English (en)
Other versions
BG64436B1 (en
Inventor
Burt Adelman
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of BG104092A publication Critical patent/BG104092A/bg
Publication of BG64436B1 publication Critical patent/BG64436B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

Изобретението се отнася до методи, съгласно коитосе прилага блокатор на CD40:CD154 свързването, например CD154 блокиращ агент, за отслабване или подобрение на придобития биоинхибиторен хуморален имунитет, насочен срещу екзогенен белтък.
BG104092A 1997-06-20 2000-01-18 Cd154 blockade therapy for the treatment of protein inhibition syndrome BG64436B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20

Publications (2)

Publication Number Publication Date
BG104092A true BG104092A (bg) 2000-10-31
BG64436B1 BG64436B1 (en) 2005-02-28

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104092A BG64436B1 (en) 1997-06-20 2000-01-18 Cd154 blockade therapy for the treatment of protein inhibition syndrome

Country Status (25)

Country Link
US (1) US20020119151A1 (bg)
EP (1) EP1034001B1 (bg)
JP (1) JP2002504910A (bg)
KR (1) KR100567998B1 (bg)
CN (2) CN1261285A (bg)
AT (1) ATE272408T1 (bg)
AU (1) AU733062B2 (bg)
BG (1) BG64436B1 (bg)
BR (1) BR9810755A (bg)
CA (1) CA2294138A1 (bg)
CZ (1) CZ295805B6 (bg)
DE (1) DE69825473T2 (bg)
EA (1) EA002512B1 (bg)
EE (1) EE9900587A (bg)
ES (1) ES2226152T3 (bg)
HK (1) HK1031825A1 (bg)
HU (1) HUP0002048A3 (bg)
IL (1) IL133305A0 (bg)
IS (1) IS2097B (bg)
NO (1) NO996274L (bg)
NZ (1) NZ502051A (bg)
PT (1) PT1034001E (bg)
SK (1) SK285962B6 (bg)
TR (1) TR199903141T2 (bg)
WO (1) WO1998058672A1 (bg)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002898A (es) * 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2004253868B2 (en) * 2003-06-13 2011-06-16 Biogen Ma Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2006033702A2 (en) 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
EA200000059A1 (ru) 2000-08-28
EP1034001A1 (en) 2000-09-13
NZ502051A (en) 2001-04-27
KR20010013964A (ko) 2001-02-26
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
ES2226152T3 (es) 2005-03-16
CZ295805B6 (cs) 2005-11-16
IL133305A0 (en) 2001-04-30
CN1261285A (zh) 2000-07-26
US20020119151A1 (en) 2002-08-29
DE69825473T2 (de) 2005-08-04
CN1651071A (zh) 2005-08-10
IS2097B (is) 2006-04-12
PT1034001E (pt) 2004-12-31
ATE272408T1 (de) 2004-08-15
BR9810755A (pt) 2000-08-15
EP1034001B1 (en) 2004-08-04
SK180399A3 (en) 2000-06-12
HK1031825A1 (en) 2001-06-29
DE69825473D1 (de) 2004-09-09
AU8153698A (en) 1999-01-04
NO996274D0 (no) 1999-12-17
BG64436B1 (en) 2005-02-28
TR199903141T2 (xx) 2000-09-21
EA002512B1 (ru) 2002-06-27
IS5274A (is) 1999-11-26
HUP0002048A2 (hu) 2000-10-28
CA2294138A1 (en) 1998-12-30
AU733062B2 (en) 2001-05-03
JP2002504910A (ja) 2002-02-12
NO996274L (no) 2000-02-18
WO1998058672A1 (en) 1998-12-30
KR100567998B1 (ko) 2006-04-07
SK285962B6 (sk) 2007-12-06
CZ458899A3 (cs) 2000-04-12

Similar Documents

Publication Publication Date Title
BG104092A (bg) Сd154 блокадна терапия за лечение на белтък инхибиторен синдром
PL328858A1 (en) Immunogenous peptides
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
ZA88798B (en) Dental anti-plaque and anti-caries agent
WO1997045137A8 (en) Methods and compositions useful for inhibition of angiogenesis
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
BG102259A (bg) Състави с контролирано освобождаване на пароксетин
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU5861799A (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
UA41355C2 (uk) Засіб для лікування нейро-сніду
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
BG102818A (bg) D-манитол и метод за неговото получаване
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
PH30101A (en) Treating classic migraine
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
ZA949564B (en) Method for treating constipation using dimeticone.
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
MXPA03006372A (es) Compuestos aromaticos simetricamente disustituidos y composiciones farmaceuticas para inhibir poli (adp-ribosa) glicohidrolasa y metodos para su uso.
WO1998006431A3 (en) Method for treating diabetes
EP0331803A3 (en) Medicament for inhibiting onset of or treating migraine headaches employing an ace inhibitor
AU5434899A (en) Cancer treatment